Regulation of Angiogenesis by Hypoxia and Hypoxia-Inducible Factors

Current Topics in Developmental Biology

Volumn 76, Issue , 2006, Pages 217-257

  Hickey, Michele M ^a,b   Simon, M Celeste ^a,b  

^a Abramson Family Cancer Research Institute   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; HYPOXIA INDUCIBLE FACTOR 1;

ANGIOGENESIS; ANIMAL; ANOXIA; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; HUMAN; ISCHEMIA; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TRANSACTIVATION; VASCULARIZATION; VON HIPPEL LINDAU DISEASE;

ANIMALS; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; HIPPEL-LINDAU DISEASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; ISCHEMIA; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; TRANS-ACTIVATION (GENETICS);

EID: 33751192872     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0070-2153(06)76007-0     Document Type: Review

References (266)

1. Acker T., Diez-Juan A., Aragones J., Tjwa M., Brusselmans K., Moons L., Fukumura D., Moreno-Murciano M.P., Herbert J.M., Burger A., Riedel J., Elvert G., et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 8 (2005) 131-141
2. Adelman D.M., Maltepe E., and Simon M.C. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev. 13 (1999) 2478-2483
3. Adelman D.M., Gertsenstein M., Nagy A., Simon M.C., and Maltepe E. Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses. Genes Dev. 14 (2000) 3191-3203
4. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., and Semenza G.L. Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61 (2001) 2911-2916
5. Agrawal N., Bettegowda C., Cheong I., Geschwind J.F., Drake C.G., Hipkiss E.L., Tatsumi M., Dang L.H., Diaz Jr. L.A., Pomper M., Abusedera M., Wahl R.L., et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. USA 101 (2004) 15172-15177
6. Alfranca A., Gutierrez M.D., Vara A., Aragones J., Vidal F., and Landazuri M.O. c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription. Mol. Cell. Biol. 22 (2002) 12-22
7. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., and Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392 (1998) 405-408
8. Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A., Bunn H.F., and Livingston D.M. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA 93 (1996) 12969-12973
9. Arsham A.M., Plas D.R., Thompson C.B., and Simon M.C. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J. Biol. Chem. 277 (2002) 15162-15170
10. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., and Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
11. Bangoura G., Yang L.Y., Huang G.W., and Wang W. Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma. World J. Gastroenterol. 10 (2004) 525-530
12. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., and Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87 (1996) 3336-3343
13. Ben-Yosef Y., Lahat N., Shapiro S., Bitterman H., and Miller A. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ. Res. 90 (2002) 784-791
14. Bergeron M., Yu A.Y., Solway K.E., Semenza G.L., and Sharp F.R. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur. J. Neurosci. 11 (1999) 4159-4170
15. Bergeron M., Gidday J.M., Yu A.Y., Semenza G.L., Ferriero D.M., and Sharp F.R. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. Ann. Neurol. 48 (2000) 285-296
16. Bettegowda C., Dang L.H., Abrams R., Huso D.L., Dillehay L., Cheong I., Agrawal N., Borzillary S., McCaffery J.M., Watson E.L., Lin K.S., Bunz F., et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc. Natl. Acad. Sci. USA 100 (2003) 15083-15088
17. Bingle L., Lewis C.E., Corke K.P., Reed M.W., and Brown N.J. Macrophages promote angiogenesis in human breast tumour spheroids in vivo. Br. J. Cancer 94 (2006) 101-107
18. Blouw B., Song H., Tihan T., Bosze J., Ferrara N., Gerber H.P., Johnson R.S., and Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4 (2003) 133-146
19. Bolli R., Manchikalapudi S., Tang X.L., Takano H., Qiu Y., Guo Y., Zhang Q., and Jadoon A.K. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ. Res. 81 (1997) 1094-1107
20. Bos R., Zhong H., Hanrahan C.F., Mommers E.C., Semenza G.L., Pinedo H.M., Abeloff M.D., Simons J.W., van Diest P.J., and van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. 93 (2001) 309-314
21. Bracken C.P., Whitelaw M.L., and Peet D.J. Activity of hypoxia-inducible factor 2alpha is regulated by association with the NF-kappaB essential modulator. J. Biol. Chem. 280 (2005) 14240-14251
22. Brahimi-Horn M.C., and Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int. Rev. Cytol. 242 (2005) 157-213
23. Bruick R.K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. USA 97 (2000) 9082-9087
24. Bruick R.K., and McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294 (2001) 1337-1340
25. Brunelle J.K., Bell E.L., Quesada N.M., Vercauteren K., Tiranti V., Zeviani M., Scarpulla R.C., and Chandel N.S. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 1 (2005) 409-414
26. Caniggia I., Grisaru-Gravnosky S., Kuliszewsky M., Post M., and Lye S.J. Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J. Clin. Invest. 103 (1999) 1641-1650
27. Caniggia I., Mostachfi H., Winter J., Gassmann M., Lye S.J., Kuliszewski M., and Post M. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J. Clin. Invest. 105 (2000) 577-587
28. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6 (2000) 389-395
29. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
30. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
31. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
32. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
33. Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H., and Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol. Cell. Biol. 20 (2000) 402-415
34. Cejudo-Martin P., Morales-Ruiz M., Ros J., Navasa M., Fernandez-Varo G., Fuster J., Rivera F., Arroyo V., Rodes J., and Jimenez W. Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. Hepatology 36 (2002) 1172-1179
35. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., and Gurtner G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10 (2004) 858-864
36. Chandel N.S., Maltepe E., Goldwasser E., Mathieu C.E., Simon M.C., and Schumacker P.T. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl. Acad. Sci. USA 95 (1998) 11715-11720
37. Chandel N.S., McClintock D.S., Feliciano C.E., Wood T.M., Melendez J.A., Rodriguez A.M., and Schumacker P.T. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2 sensing. J. Biol. Chem. 275 (2000) 25130-25138
38. Chen C., Pore N., Behrooz A., Ismail-Beigi F., and Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 276 (2001) 9519-9525
39. Choi K., Kennedy M., Kazarov A., Papadimitriou J.C., and Keller G. A common precursor for hematopoietic and endothelial cells. Development 125 (1998) 725-732
40. Clifford S.C., Cockman M.E., Smallwood A.C., Mole D.R., Woodward E.R., Maxwell P.H., Ratcliffe P.J., and Maher E.R. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10 (2001) 1029-1038
41. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., Maher E.R., Pugh C.W., Ratcliffe P.J., and Maxwell P.H. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275 (2000) 25733-25741
42. Compernolle V., Brusselmans K., Acker T., Hoet P., Tjwa M., Beck H., Plaisance S., Dor Y., Keshet E., Lupu F., Nemery B., Dewerchin M., et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8 (2002) 702-710
43. Compernolle V., Brusselmans K., Franco D., Moorman A., Dewerchin M., Collen D., and Carmeliet P. Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha. Cardiovasc. Res. 60 (2003) 569-579
44. Conway E.M., Collen D., and Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49 (2001) 507-521
45. Covello K.L., Simon M.C., and Keith B. Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res. 65 (2005) 2277-2286
46. Covello K.L., Kehler J., Yu H., Gordan J.D., Arsham A.M., Hu C.J., Labosky P.A., Simon M.C., and Keith B. HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20 (2006) 557-570
47. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., Haase V.H., Jaenisch R., Corr M., Nizet V., Firestein G.S., Gerber H.P., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112 (2003) 645-657
48. Crews S.T. Control of cell lineage-specific development and transcription by bHLH-PAS proteins. Genes Dev. 12 (1998) 607-620
49. Crews S.T., and Fan C.M. Remembrance of things PAS: Regulation of development by bHLH-PAS proteins. Curr. Opin. Genet. Dev. 9 (1999) 580-587
50. Currie M.J., Gunningham S.P., Turner K., Han C., Scott P.A., Robinson B.A., Chong W., Harris A.L., and Fox S.B. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J. Pathol. 198 (2002) 502-510
51. Dachs G.U., Patterson A.V., Firth J.D., Ratcliffe P.J., Townsend K.M., Stratford I.J., and Harris A.L. Targeting gene expression to hypoxic tumor cells. Nat. Med. 3 (1997) 515-520
52. Damert A., Miquerol L., Gertsenstein M., Risau W., and Nagy A. Insufficient VEGFA activity in yolk sac endoderm compromises haematopoietic and endothelial differentiation. Development 129 (2002) 1881-1892
53. Dang C.V., Lewis B.C., Dolde C., Dang G., and Shim H. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J. Bioenerg. Biomembr. 29 (1997) 345-354
54. Dang L.H., Bettegowda C., Huso D.L., Kinzler K.W., and Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. USA 98 (2001) 15155-15160
55. De Palma M., Venneri M.A., Roca C., and Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat. Med. 9 (2003) 789-795
56. De Palma M., Venneri M.A., Galli R., Sergi L.S., Politi L.S., Sampaolesi M., and Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8 (2005) 211-226
57. de Paulsen N., Brychzy A., Fournier M.C., Klausner R.D., Gnarra J.R., Pause A., and Lee S. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc. Natl. Acad. Sci. USA 98 (2001) 1387-1392
58. Desbaillets I., Diserens A.C., de Tribolet N., Hamou M.F., and Van Meir E.G. Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene 18 (1999) 1447-1456
59. Duan D.R., Humphrey J.S., Chen D.Y., Weng Y., Sukegawa J., Lee S., Gnarra J.R., Linehan W.M., and Klausner R.D. Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl. Acad. Sci. USA 92 (1995) 6459-6463
60. Duan L.J., Nagy A., and Fong G.H. Gastrulation and angiogenesis, not endothelial specification, is sensitive to partial deficiency in vascular endothelial growth factor-a in mice. Biol. Reprod. 69 (2003) 1852-1858
61. Ebert B.L., and Bunn H.F. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol. Cell. Biol. 18 (1998) 4089-4096
62. Elson D.A., Ryan H.E., Snow J.W., Johnson R., and Arbeit J.M. Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res. 60 (2000) 6189-6195
63. Elson D.A., Thurston G., Huang L.E., Ginzinger D.G., McDonald D.M., Johnson R.S., and Arbeit J.M. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev. 15 (2001) 2520-2532
64. Elvert G., Kappel A., Heidenreich R., Englmeier U., Lanz S., Acker T., Rauter M., Plate K., Sieweke M., Breier G., and Flamme I. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J. Biol. Chem. 278 (2003) 7520-7530
65. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., and Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA 94 (1997) 4273-4278
66. Ema M., Hirota K., Mimura J., Abe H., Yodoi J., Sogawa K., Poellinger L., and Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: Their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 18 (1999) 1905-1914
67. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., Tian Y.M., Masson N., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
68. Faloon P., Arentson E., Kazarov A., Deng C.X., Porcher C., Orkin S., and Choi K. Basic fibroblast growth factor positively regulates hematopoietic development. Development 127 (2000) 1931-1941
69. Favier J., Kempf H., Corvol P., and Gasc J.M. Coexpression of endothelial PAS protein 1 with essential angiogenic factors suggests its involvement in human vascular development. Dev. Dyn. 222 (2001) 377-388
70. Feldser D., Agani F., Iyer N.V., Pak B., Ferreira G., and Semenza G.L. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 59 (1999) 3915-3918
71. Ferrara N. Vascular endothelial growth factor: Molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237 (1999) 1-30
72. Ferrara N., and Gerber H.P. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 106 (2001) 148-156
73. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
74. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., and Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
75. Flamme I., Frohlich T., von Reutern M., Kappel A., Damert A., and Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech. Dev. 63 (1997) 51-60
76. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
77. Fong G.H., Rossant J., Gertsenstein M., and Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376 (1995) 66-70
78. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., and Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16 (1996) 4604-4613
79. Garayoa M., Martinez A., Lee S., Pio R., An W.G., Neckers L., Trepel J., Montuenga L.M., Ryan H., Johnson R., Gassmann M., and Cuttitta F. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: A possible promotion mechanism of carcinogenesis. Mol. Endocrinol. 14 (2000) 848-862
80. Gerald D., Berra E., Frapart Y.M., Chan D.A., Giaccia A.J., Mansuy D., Pouyssegur J., Yaniv M., and Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118 (2004) 781-794
81. Gerber H.P., Condorelli F., Park J., and Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 272 (1997) 23659-23667
82. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Talks K., Pezzella F., Gatter K.C., and Harris A.L. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85 (2001) 881-890
83. Gidday J.M., Fitzgibbons J.C., Shah A.R., and Park T.S. Neuroprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat. Neurosci. Lett. 168 (1994) 221-224
84. Gidday J.M., Shah A.R., Maceren R.G., Wang Q., Pelligrino D.A., Holtzman D.M., and Park T.S. Nitric oxide mediates cerebral ischemic tolerance in a neonatal rat model of hypoxic preconditioning. J. Cereb. Blood Flow Metab. 19 (1999) 331-340
85. Gnarra J.R., Ward J.M., Porter F.D., Wagner J.R., Devor D.E., Grinberg A., Emmert-Buck M.R., Westphal H., Klausner R.D., and Linehan W.M. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA 94 (1997) 9102-9107
86. Goda N., Ryan H.E., Khadivi B., McNulty W., Rickert R.C., and Johnson R.S. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 23 (2003) 359-369
87. Griffiths L., Binley K., Iqball S., Kan O., Maxwell P., Ratcliffe P., Lewis C., Harris A., Kingsman S., and Naylor S. The macrophage-a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7 (2000) 255-262
88. Grimm C., Wenzel A., Groszer M., Mayser H., Seeliger M., Samardzija M., Bauer C., Gassmann M., and Reme C.E. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat. Med. 8 (2002) 718-724
89. Grimm C., Hermann D.M., Bogdanova A., Hotop S., Kilic U., Wenzel A., Kilic E., and Gassmann M. Neuroprotection by hypoxic preconditioning: HIF-1 and erythropoietin protect from retinal degeneration. Semin. Cell Dev. Biol. 16 (2005) 531-538
90. Grunewald M., Avraham I., Dor Y., Bachar-Lustig E., Itin A., Yung S., Chimenti S., Landsman L., Abramovitch R., and Keshet E. VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell 124 (2006) 175-189
91. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L., and Bradfield C.A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 7 (1998) 205-213
92. Gu Y.Z., Hogenesch J.B., and Bradfield C.A. The PAS superfamily: Sensors of environmental and developmental signals. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 519-561
93. Gunaratnam L., Morley M., Franovic A., de Paulsen N., Mekhail K., Parolin D.A., Nakamura E., Lorimer I.A., and Lee S. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 278 (2003) 44966-44974
94. Gustafsson M.V., Zheng X., Pereira T., Gradin K., Jin S., Lundkvist J., Ruas J.L., Poellinger L., Lendahl U., and Bondesson M. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell 9 (2005) 617-628
95. Guzy R.D., Hoyos B., Robin E., Chen H., Liu L., Mansfield K.D., Simon M.C., Hammerling U., and Schumacker P.T. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 1 (2005) 401-408
96. Haase V.H., Glickman J.N., Socolovsky M., and Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. USA 98 (2001) 1583-1588
97. Haddad J.J., and Land S.C. A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha. FEBS Lett. 505 (2001) 269-274
98. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
99. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002) 38-47
100. Herbst R.S., Hess K.R., Tran H.T., Tseng J.E., Mullani N.A., Charnsangavej C., Madden T., Davis D.W., McConkey D.J., O'Reilly M.S., Ellis L.M., Pluda J., et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 20 (2002) 3792-3803
101. Hewitson K.S., McNeill L.A., Riordan M.V., Tian Y.M., Bullock A.N., Welford R.W., Elkins J.M., Oldham N.J., Bhattacharya S., Gleadle J.M., Ratcliffe P.J., Pugh C.W., et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277 (2002) 26351-26355
102. Hockel M., and Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93 (2001) 266-276
103. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56 (1996) 4509-4515
104. Hockel M., Schlenger K., Hockel S., and Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59 (1999) 4525-4528
105. Hoffman M.A., Ohh M., Yang H., Klco J.M., Ivan M., and Kaelin Jr. W.G. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10 (2001) 1019-1027
106. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99 (2002) 11393-11398
107. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., and Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 23 (2003) 9361-9374
108. Hu C.J., Iyer S., Sataur A., Covello K.L., Chodosh L.A., and Simon M.C. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1{alpha}) and HIF-2{alpha} in stem cells. Mol. Cell. Biol. 26 (2006) 3514-3526
109. Huang L.E., Gu J., Schau M., and Bunn H.F. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95 (1998) 7987-7992
110. Huang Y., Hickey R.P., Yeh J.L., Liu D., Dadak A., Young L.H., Johnson R.S., and Giordano F.J. Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J. 18 (2004) 1138-1140
111. Huber T.L., Kouskoff V., Fehling H.J., Palis J., and Keller G. Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. Nature 432 (2004) 625-630
112. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
113. Iliopoulos O., Kibel A., Gray S., and Kaelin Jr. W.G. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1 (1995) 822-826
114. Iliopoulos O., Levy A.P., Jiang C., Kaelin Jr. W.G., and Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93 (1996) 10595-10599
115. Ivan M., and Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor protein. Curr. Opin. Genet. Dev. 11 (2001) 27-34
116. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., and Kaelin Jr. W.G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292 (2001) 464-468
117. Ivan M., Haberberger T., Gervasi D.C., Michelson K.S., Gunzler V., Kondo K., Yang H., Sorokina I., Conaway R.C., Conaway J.W., and Kaelin Jr. W.G. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. USA 99 (2002) 13459-13464
118. Iwai K., Yamanaka K., Kamura T., Minato N., Conaway R.C., Conaway J.W., Klausner R.D., and Pause A. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. USA 96 (1999) 12436-12441
119. Iyer N.V., Kotch L.E., Agani F., Leung S.W., Laughner E., Wenger R.H., Gassmann M., Gearhart J.D., Lawler A.M., Yu A.Y., and Semenza G.L. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12 (1998) 149-162
120. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
121. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 9 (2003) 685-693
122. Jain S., Maltepe E., Lu M.M., Simon C., and Bradfield C.A. Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mech. Dev. 73 (1998) 117-123
123. Jiang B.H., Rue E., Wang G.L., Roe R., and Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271 (1996) 17771-17778
124. Jiang B.H., Agani F., Passaniti A., and Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res. 57 (1997) 5328-5335
125. Jiang B.H., Zheng J.Z., Leung S.W., Roe R., and Semenza G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 272 (1997) 19253-19260
126. Jung Y., Isaacs J.S., Lee S., Trepel J., Liu Z.G., and Neckers L. Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem. J. 370 (2003) 1011-1017
127. Jung Y.J., Isaacs J.S., Lee S., Trepel J., and Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17 (2003) 2115-2117
128. Kaelin Jr. W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2 (2002) 673-682
129. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., and Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 274 (1999) 6519-6525
130. Kamura T., Conrad M.N., Yan Q., Conaway R.C., and Conaway J.W. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev. 13 (1999) 2928-2933
131. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., and Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. USA 97 (2000) 10430-10435
132. Kennedy M., Firpo M., Choi K., Wall C., Robertson S., Kabrun N., and Keller G. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature 386 (1997) 488-493
133. Kewley R.J., Whitelaw M.L., and Chapman-Smith A. The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int. J. Biochem. Cell Biol. 36 (2004) 189-204
134. Khakoo A.Y., and Finkel T. Endothelial progenitor cells. Annu. Rev. Med. 56 (2005) 79-101
135. Kibel A., Iliopoulos O., DeCaprio J.A., and Kaelin Jr. W.G. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269 (1995) 1444-1446
136. Kieran M.W., Perkins A.C., Orkin S.H., and Zon L.I. Thrombopoietin rescues in vitro erythroid colony formation from mouse embryos lacking the erythropoietin receptor. Proc. Natl. Acad. Sci. USA 93 (1996) 9126-9131
137. Kietzmann T., Roth U., and Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 94 (1999) 4177-4185
138. Kietzmann T., Knabe W., and Schmidt-Kastner R. Hypoxia and hypoxia-inducible factor modulated gene expression in brain: Involvement in neuroprotection and cell death. Eur. Arch. Psychiatry Clin. Neurosci. 251 (2001) 170-178
139. Kietzmann T., Samoylenko A., Roth U., and Jungermann K. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood 101 (2003) 907-914
140. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
141. Kim W., and Kaelin Jr. W.G. The von Hippel-Lindau tumor suppressor protein: New insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13 (2003) 55-60
142. Kondo K., Klco J., Nakamura E., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
143. Kondo K., Kim W.Y., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1 (2003) E83
144. Koshiji M., Kageyama Y., Pete E.A., Horikawa I., Barrett J.C., and Huang L.E. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23 (2004) 1949-1956
145. Kozak K.R., Abbott B., and Hankinson O. ARNT-deficient mice and placental differentiation. Dev. Biol. 191 (1997) 297-305
146. Kung A.L., Wang S., Klco J.M., Kaelin W.G., and Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6 (2000) 1335-1340
147. Laderoute K.R., Calaoagan J.M., Gustafson-Brown C., Knapp A.M., Li G.C., Mendonca H.L., Ryan H.E., Wang Z., and Johnson R.S. The response of c-jun/AP-1 to chronic hypoxia is hypoxia-inducible factor 1 alpha dependent. Mol. Cell. Biol. 22 (2002) 2515-2523
148. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., and Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16 (2002) 1466-1471
149. Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., Stackhouse T., Kuzmin I., Modi W., Geil L., Schmidt L., Zhou F., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
150. Laughner E., Taghavi P., Chiles K., Mahon P.C., and Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21 (2001) 3995-4004
151. Lee S.H., Wolf P.L., Escudero R., Deutsch R., Jamieson S.W., and Thistlethwaite P.A. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N. Engl. J. Med. 342 (2000) 626-633
152. Leek R.D., and Harris A.L. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia 7 (2002) 177-189
153. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., and Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56 (1996) 4625-4629
154. Leek R.D., Hunt N.C., Landers R.J., Lewis C.E., Royds J.A., and Harris A.L. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 190 (2000) 430-436
155. Leek R.D., Talks K.L., Pezzella F., Turley H., Campo L., Brown N.S., Bicknell R., Taylor M., Gatter K.C., and Harris A.L. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res. 62 (2002) 1326-1329
156. Lemmon M.J., van Zijl P., Fox M.E., Mauchline M.L., Giaccia A.J., Minton N.P., and Brown J.M. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 4 (1997) 791-796
157. Levy N.S., Chung S., Furneaux H., and Levy A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273 (1998) 6417-6423
158. Lewis J.S., Landers R.J., Underwood J.C., Harris A.L., and Lewis C.E. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 192 (2000) 150-158
159. Lewis M.D., and Roberts B.J. Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity. Oncogene 23 (2004) 2315-2323
160. Li J., Post M., Volk R., Gao Y., Li M., Metais C., Sato K., Tsai J., Aird W., Rosenberg R.D., Hampton T.G., Sellke F., et al. PR39, a peptide regulator of angiogenesis. Nat. Med. 6 (2000) 49-55
161. Lin C.S., Lim S.K., D'Agati V., and Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev. 10 (1996) 154-164
162. Lisztwan J., Imbert G., Wirbelauer C., Gstaiger M., and Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13 (1999) 1822-1833
163. Lonergan K.M., Iliopoulos O., Ohh M., Kamura T., Conaway R.C., Conaway J.W., and Kaelin Jr. W.G. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18 (1998) 732-741
164. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7 (2001) 1194-1201
165. Mack F.A., Rathmell W.K., Arsham A.M., Gnarra J., Keith B., and Simon M.C. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 3 (2003) 75-88
166. Mack F.A., Patel J.H., Biju M.P., Haase V.H., and Simon M.C. Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27. Mol. Cell. Biol. 25 (2005) 4565-4578
167. Mahon P.C., Hirota K., and Semenza G.L. FIH-1: A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15 (2001) 2675-2686
168. Maltepe E., and Simon M.C. Oxygen, genes, and development: An analysis of the role of hypoxic gene regulation during murine vascular development. J. Mol. Med. 76 (1998) 391-401
169. Maltepe E., Schmidt J.V., Baunoch D., Bradfield C.A., and Simon M.C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386 (1997) 403-407
170. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., Wykoff C.C., Maher E.R., Harris A.L., Ratcliffe P.J., and Maxwell P.H. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1 (2002) 459-468
171. Mansfield K.D., Guzy R.D., Pan Y., Young R.M., Cash T.P., Schumacker P.T., and Simon M.C. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab. 1 (2005) 393-399
172. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., and Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
173. Marti H.J., Bernaudin M., Bellail A., Schoch H., Euler M., Petit E., and Risau W. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am. J. Pathol. 156 (2000) 965-976
174. Martin C., Yu A.Y., Jiang B.H., Davis L., Kimberly D., Hohimer A.R., and Semenza G.L. Cardiac hypertrophy in chronically anemic fetal sheep: Increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1. Am. J. Obstet. Gynecol. 178 (1998) 527-534
175. Masson N., and Ratcliffe P.J. HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. J. Cell Sci. 116 (2003) 3041-3049
176. Masson N., Willam C., Maxwell P.H., Pugh C.W., and Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20 (2001) 5197-5206
177. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., and Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94 (1997) 8104-8109
178. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
179. McNeill L.A., Hewitson K.S., Claridge T.D., Seibel J.F., Horsfall L.E., and Schofield C.J. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem. J. 367 (2002) 571-575
180. Melillo G., Musso T., Sica A., Taylor L.S., Cox G.W., and Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182 (1995) 1683-1693
181. Melillo G., Taylor L.S., Brooks A., Musso T., Cox G.W., and Varesio L. Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J. Biol. Chem. 272 (1997) 12236-12243
182. Miquerol L., Langille B.L., and Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127 (2000) 3941-3946
183. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
184. Moeller B.J., Dreher M.R., Rabbani Z.N., Schroeder T., Cao Y., Li C.Y., and Dewhirst M.W. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8 (2005) 99-110
185. Morita M., Ohneda O., Yamashita T., Takahashi S., Suzuki N., Nakajima O., Kawauchi S., Ema M., Shibahara S., Udono T., Tomita K., Tamai M., et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 22 (2003) 1134-1146
186. Murre C., McCaw P.S., Vaessin H., Caudy M., Jan L.Y., Jan Y.N., Cabrera C.V., Buskin J.N., Hauschka S.D., Lassar A.B., Weintraub H., and Baltimore D. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 58 (1989) 537-544
187. O'Rourke J.F., Tian Y.M., Ratcliffe P.J., and Pugh C.W. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: Comparison with hypoxia-inducible factor-1alpha. J. Biol. Chem. 274 (1999) 2060-2071
188. Ohh M., Yauch R.L., Lonergan K.M., Whaley J.M., Stemmer-Rachamimov A.O., Louis D.N., Gavin B.J., Kley N., Kaelin Jr. W.G., and Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1 (1998) 959-968
189. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., Pavletich N., Chau V., and Kaelin W.G. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2 (2000) 423-427
190. Onita T., Ji P.G., Xuan J.W., Sakai H., Kanetake H., Maxwell P.H., Fong G.H., Gabril M.Y., Moussa M., and Chin J.L. Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer. Clin. Cancer Res. 8 (2002) 471-480
191. Ozaki H., Yu A.Y., Della N., Ozaki K., Luna J.D., Yamada H., Hackett S.F., Okamoto N., Zack D.J., Semenza G.L., and Campochiaro P.A. Hypoxia inducible factor-1alpha is increased in ischemic retina: Temporal and spatial correlation with VEGF expression. Invest. Ophthalmol. Vis. Sci. 40 (1999) 182-189
192. Pause A., Lee S., Worrell R.A., Chen D.Y., Burgess W.H., Linehan W.M., and Klausner R.D. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA 94 (1997) 2156-2161
193. Peng J., Zhang L., Drysdale L., and Fong G.H. The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc. Natl. Acad. Sci. USA 97 (2000) 8386-8391
194. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4 (2004) 71-78
195. Pugh C.W., O'Rourke J.F., Nagao M., Gleadle J.M., and Ratcliffe P.J. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J. Biol. Chem. 272 (1997) 11205-11214
196. Rafii S., and Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9 (2003) 702-712
197. Ramirez-Bergeron D.L., Runge A., Dahl K.D., Fehling H.J., Keller G., and Simon M.C. Hypoxia affects mesoderm and enhances hemangioblast specification during early development. Development 131 (2004) 4623-4634
198. Ramirez-Bergeron D.L., Runge A., Adelman D.M., Gohil M., and Simon M.C. HIF-dependent hematopoietic factors regulate the development of the embryonic vasculature. Dev. Cell 11 1 (2006) 81-92
199. Rankin E.B., Higgins D.F., Walisser J.A., Johnson R.S., Bradfield C.A., and Haase V.H. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol. Cell. Biol. 25 (2005) 3163-3172
200. Rankin E.B., Tomaszewski J.E., and Haase V.H. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res. 66 (2006) 2576-2583
201. Rathmell W.K., Hickey M.M., Bezman N.A., Chmielecki C.A., Carraway N.C., and Simon M.C. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res. 64 (2004) 8595-8603
202. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., Pugh C.W., Maxwell P.H., Harris A.L., and Ratcliffe P.J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25 (2005) 5675-5686
203. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14 (2000) 34-44
204. Reyes M., Dudek A., Jahagirdar B., Koodie L., Marker P.H., and Verfaillie C.M. Origin of endothelial progenitors in human postnatal bone marrow. J. Clin. Invest. 109 (2002) 337-346
205. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
206. Ryan H.E., Lo J., and Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17 (1998) 3005-3015
207. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., and Johnson R.S. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60 (2000) 4010-4015
208. Sabin F. Studies on the origin of blood vessels and of red corpuscles as seen in the living blastoderm of the chick during the second day of incubation. Contrib. Embryol. 9 (1920) 213-262
209. Salceda S., and Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272 (1997) 22642-22647
210. Schipani E., Ryan H.E., Didrickson S., Kobayashi T., Knight M., and Johnson R.S. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev. 15 (2001) 2865-2876
211. Schulz R., Cohen M.V., Behrends M., Downey J.M., and Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc. Res. 52 (2001) 181-198
212. Scortegagna M., Ding K., Oktay Y., Gaur A., Thurmond F., Yan L.J., Marck B.T., Matsumoto A.M., Shelton J.M., Richardson J.A., Bennett M.J., and Garcia J.A. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat. Genet. 35 (2003) 331-340
213. Scortegagna M., Morris M.A., Oktay Y., Bennett M., and Garcia J.A. The HIF family member EPAS1/HIF-2alpha is required for normal hematopoiesis in mice. Blood 102 (2003) 1634-1640
214. Scortegagna M., Ding K., Zhang Q., Oktay Y., Bennett M.J., Bennett M., Shelton J.M., Richardson J.A., Moe O., and Garcia J.A. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105 (2005) 3133-3140
215. Seagroves T.N., Hadsell D., McManaman J., Palmer C., Liao D., McNulty W., Welm B., Wagner K.U., Neville M., and Johnson R.S. HIF1alpha is a critical regulator of secretory differentiation and activation, but not vascular expansion, in the mouse mammary gland. Development 130 (2003) 1713-1724
216. Semenza G.L. HIF-1 and human disease: One highly involved factor. Genes Dev. 14 (2000) 1983-1991
217. Semenza G.L. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol. Med. 8 (2002) S62-S67
218. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
219. Semenza G.L., and Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12 (1992) 5447-5454
220. Semenza G.L., Nejfelt M.K., Chi S.M., and Antonarakis S.E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc. Natl. Acad. Sci. USA 88 (1991) 5680-5684
221. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., and Schuh A.C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376 (1995) 62-66
222. Shyu K.G., Wang M.T., Wang B.W., Chang C.C., Leu J.G., Kuan P., and Chang H. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc. Res. 54 (2002) 576-583
223. Simons M. Angiogenesis: Where do we stand now?. Circulation 111 (2005) 1556-1566
224. Sowter H.M., Ratcliffe P.J., Watson P., Greenberg A.H., and Harris A.L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61 (2001) 6669-6673
225. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., and Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425 (2003) 307-311
226. Stebbins C.E., Kaelin Jr. W.G., and Pavletich N.P. Structure of the VHL-elonginC-elonginB complex: Implications for VHL tumor suppressor function. Science 284 (1999) 455-461
227. Stein I., Itin A., Einat P., Skaliter R., Grossman Z., and Keshet E. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia. Mol. Cell. Biol. 18 (1998) 3112-3119
228. Stickle N.H., Chung J., Klco J.M., Hill R.P., Kaelin Jr. W.G., and Ohh M. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol. Cell. Biol. 24 (2004) 3251-3261
229. Stiehl D.P., Jelkmann W., Wenger R.H., and Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. 512 (2002) 157-162
230. Sun X., Kanwar J.R., Leung E., Lehnert K., Wang D., and Krissansen G.W. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther. 8 (2001) 638-645
231. Sun X., Liu M., Wei Y., Liu F., Zhi X., Xu R., and Krissansen G.W. Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas. Cancer Gene Ther. 13 (2006) 428-435
232. Takahashi T., Kalka C., Masuda H., Chen D., Silver M., Kearney M., Magner M., Isner J.M., and Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5 (1999) 434-438
233. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., and Harris A.L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157 (2000) 411-421
234. Tang N., Wang L., Esko J., Giordano F.J., Huang Y., Gerber H.P., Ferrara N., and Johnson R.S. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6 (2004) 485-495
235. Tang N., Mack F., Haase V.H., Simon M.C., and Johnson R.S. pVHL function is essential for endothelial extracellular matrix deposition. Mol. Cell. Biol. 26 (2006) 2519-2530
236. Tanimoto K., Makino Y., Pereira T., and Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19 (2000) 4298-4309
237. Tateishi-Yuyama E., Matsubara H., Murohara T., Ikeda U., Shintani S., Masaki H., Amano K., Kishimoto Y., Yoshimoto K., Akashi H., Shimada K., Iwasaka T., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 360 (2002) 427-435
238. Tian H., McKnight S.L., and Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11 (1997) 72-82
239. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., and McKnight S.L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12 (1998) 3320-3324
240. Tomita S., Ueno M., Sakamoto M., Kitahama Y., Ueki M., Maekawa N., Sakamoto H., Gassmann M., Kageyama R., Ueda N., Gonzalez F.J., and Takahama Y. Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol. Cell. Biol. 23 (2003) 6739-6749
241. Treins C., Giorgetti-Peraldi S., Murdaca J., Semenza G.L., and Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277 (2002) 27975-27981
242. Turner K.J., Moore J.W., Jones A., Taylor C.F., Cuthbert-Heavens D., Han C., Leek R.D., Gatter K.C., Maxwell P.H., Ratcliffe P.J., Cranston D., and Harris A.L. Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 62 (2002) 2957-2961
243. Unruh A., Ressel A., Mohamed H.G., Johnson R.S., Nadrowitz R., Richter E., Katschinski D.M., and Wenger R.H. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22 (2003) 3213-3220
244. Urbich C., and Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ. Res. 95 (2004) 343-353
245. Veikkola T., Karkkainen M., Claesson-Welsh L., and Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60 (2000) 203-212
246. Vincent K.A., Shyu K.G., Luo Y., Magner M., Tio R.A., Jiang C., Goldberg M.A., Akita G.Y., Gregory R.J., and Isner J.M. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 102 (2000) 2255-2261
247. Walmsley S.R., Print C., Farahi N., Peyssonnaux C., Johnson R.S., Cramer T., Sobolewski A., Condliffe A.M., Cowburn A.S., Johnson N., and Chilvers E.R. Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J. Exp. Med. 201 (2005) 105-115
248. Wang G.L., and Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270 (1995) 1230-1237
249. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514
250. Wenger R.H., and Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem. 378 (1997) 609-616
251. Wiesener M.S., Munchenhagen P.M., Berger I., Morgan N.V., Roigas J., Schwiertz A., Jurgensen J.S., Gruber G., Maxwell P.H., Loning S.A., Frei U., Maher E.R., et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 61 (2001) 5215-5222
252. Wiesener M.S., Jurgensen J.S., Rosenberger C., Scholze C.K., Horstrup J.H., Warnecke C., Mandriota S., Bechmann I., Frei U.A., Pugh C.W., Ratcliffe P.J., Bachmann S., et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J. 17 (2003) 271-273
253. Willam C., Masson N., Tian Y.M., Mahmood S.A., Wilson M.I., Bicknell R., Eckardt K.U., Maxwell P.H., Ratcliffe P.J., and Pugh C.W. Peptide blockade of HIFalpha degradation modulates cellular metabolism and angiogenesis. Proc. Natl. Acad. Sci. USA 99 (2002) 10423-10428
254. Wu H., Liu X., Jaenisch R., and Lodish H.F. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83 (1995) 59-67
255. Wu H., Lee S.H., Gao J., Liu X., and Iruela-Arispe M.L. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126 (1999) 3597-3605
256. Yamaguchi T.P., Dumont D.J., Conlon R.A., Breitman M.L., and Rossant J. flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development 118 (1993) 489-498
257. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., and Park J.W. YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95 (2003) 516-525
258. Yu A.Y., Frid M.G., Shimoda L.A., Wiener C.M., Stenmark K., and Semenza G.L. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am. J. Physiol. 275 (1998) L818-L826
259. Yu A.Y., Shimoda L.A., Iyer N.V., Huso D.L., Sun X., McWilliams R., Beaty T., Sham J.S., Wiener C.M., Sylvester J.T., and Semenza G.L. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J. Clin. Invest. 103 (1999) 691-696
260. Yu F., White S.B., Zhao Q., and Lee F.S. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA 98 (2001) 9630-9635
261. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., and Semenza G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer 88 (2000) 2606-2618
262. Zagzag D., Krishnamachary B., Yee H., Okuyama H., Chiriboga L., Ali M.A., Melamed J., and Semenza G.L. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65 (2005) 6178-6188
263. Zelzer E., Levy Y., Kahana C., Shilo B.Z., Rubinstein M., and Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J. 17 (1998) 5085-5094
264. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., and Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 (1999) 5830-5835
265. Zhou J., Schmid T., and Brune B. Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia inducible factor-1alpha through a nuclear factor-kappaB-dependent pathway. Mol. Biol. Cell 14 (2003) 2216-2225
266. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A.R., Ryan H.E., Johnson R.S., Jefferson A.B., Stokoe D., and Giaccia A.J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14 (2000) 391-396